Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,101 to 1,120 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Computational and network pharmacology studies of Phyllanthus emblica to tackle SARS-CoV-2. | Phytomed Plus | 2021 | 35399824 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy Therapeutics in India: Parental Hopes and Despair! | Ann Neurosci | 2021 | 35341234 | PubTator, text mining | PubMed |
| Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries. | Front Pharmacol | 2021 | 35185551 | PubTator, text mining | PubMed |
| Engineering Crystal Packing in RNA-Protein Complexes II: A Historical Perspective from the Structural Studies of the Spliceosome. | Crystals (Basel) | 2021 | 35154816 | PubTator, text mining | PubMed |
| Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment-A Pilot Study. | Front Neurol | 2021 | 35140677 | PubTator, text mining | PubMed |
| A Compound Heterozygous Mutation in Calpain 1 Identifies a New Genetic Cause for Spinal Muscular Atrophy Type 4 (SMA4). | Front Genet | 2021 | 35126465 | PubTator, text mining | PubMed |
| Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries. | Front Pharmacol | 2021 | 35126102 | PubTator, text mining | PubMed |
| The Birth Prevalence of Spinal Muscular Atrophy: A Population Specific Approach in Estonia. | Front Genet | 2021 | 35003227 | PubTator, text mining | PubMed |
| PROCEEDINGS OF THE XXI CONGRESS OF THE ITALIAN ASSOCIATION OF MYOLOGY: Digital EditionDecember 01-04, 2021. | Acta Myol | 2021 | 34993420 | PubTator, text mining | PubMed |
| Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiation. | ACS Omega | 2021 | 34984269 | PubTator, text mining | PubMed |
| The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases. | Front Cell Dev Biol | 2021 | 34977000 | PubTator, text mining | PubMed |
| Suppression of Inflammatory and Fibrotic Signals by Cinnamon (Cinnamomum cassia) and Cinnamaldehyde in Cyclophosphamide-Induced Overactive Bladder in Mice. | Evid Based Complement Alternat Med | 2021 | 34976095 | PubTator, text mining | PubMed |
| Antisense Oligonucleotide-Based Therapy of Viral Infections. | Pharmaceutics | 2021 | 34959297 | PubTator, text mining | PubMed |
| Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult with 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity. | Case Rep Neurol | 2021 | 34950009 | PubTator, text mining | PubMed |
| Small Molecule Drugs Targeting Non-Coding RNAs as Treatments for Alzheimer's Disease and Related Dementias. | Genes (Basel) | 2021 | 34946953 | PubTator, text mining | PubMed |
| Small molecule splicing modifiers with systemic HTT-lowering activity. | Nat Commun | 2021 | 34911927 | PubTator, text mining | PubMed |
| Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation. | Tremor Other Hyperkinet Mov (N Y) | 2021 | 34909266 | PubTator, text mining | PubMed |
| Current landscape of clinical development and approval of advanced therapies. | Mol Ther Methods Clin Dev | 2021 | 34901306 | PubTator, text mining | PubMed |
| Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I. | J Clin Med | 2021 | 34884240 | PubTator, text mining | PubMed |
| The good, the bad, and the ugly: Evolutionary and pathological aspects of gene dosage alterations. | PLoS Genet | 2021 | 34882671 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=56